NANOPARTICULATE COMPOSITIONS OF IMMUNOSUPPRESSIVE AGENTS
Methods for stabilizing chemical compounds, particularly pharmaceutical agents, using nanoparticulate compositions are described. The nanoparticulate compositions comprise a chemical compound, such as a pharmaceutical agent, and at least one surface stabilizer. The component chemical compound exhibits chemical stability, even following prolonged storage, repeated freezing-thawing cycles, exposure to elevated temperatures, or exposure to non-physiological pH conditions.
1 - 19 . (canceled)
20 . A pharmaceutical composition of an immunosuppressive agent comprising solid particles of the agent coated with one or more surface modifiers, wherein the particles have an average effective particle size of less than about 50 nm to less than about 2 microns.
21 . The composition of claim 20 , wherein the surface modifier is selected from the group consisting of: anionic surfactants, cationic surfactants, zwitterionic surfactants, nonionic surfactants, surface active biological modifiers, and combinations thereof.
22 . The composition of claim 21 , wherein the anionic surfactant is selected from the group consisting of: alkyl sulfonates, alkyl phosphates, triethanolamine stearate, sodium lauryl sulfate, sodium dodecylsulfate, alkyl polyoxyethylene sulfates, sodium alginate, dioctyl sodium sulfosuccinate, sodium carboxymethylcellulose, and calcium carboxymethylcellulose.
23 . The composition of claim 21 , wherein the cationic surfactant is selected from the group consisting of quaternary ammonium compounds, benzalkonium chloride, cetyltrimethylammonium bromide, lauryldimethylbenzylammonium chloride, dimethyldioctadecylammomium bromide, dimethylaminoethanecarbamoyl cholesterol, and 1, 2-dialkylglycero-3-alkylphosphocholine.
24 . The composition of claim 21 , wherein the anionic surfactant is a natural or synthetic phospholipid.
25 . The composition of claim 21 , wherein the cationic surfactant is a phospholipid, and wherein the phospholipid is natural or synthetic.
26 . The composition of claim 21 , wherein the zwitterionic surfactant is a natural or synthetic phospholipid.
27 . The composition of claim 21 , wherein the nonionic surfactant is selected from the group consisting of: glyceryl esters, polyoxyethylene fatty alcohol ethers, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene fatty acid esters, sorbitan esters, glycerol monostearate, polyethylene glycols, polypropylene glycols, cetyl alcohol, cetostearyl alcohol, stearyl alcohol, aryl alkyl polyether alcohols, polyoxyethylene-polyoxypropylene copolymers, polaxamines, methylcellulose, hydroxycellulose, hydroxy propylcellulose, hydroxy propylmethylcellulose, noncrystalline cellulose, polysaccharides, starch, starch derivatives, hydroxyethylstarch, polyvinyl alcohol, and polyvinylpyrrolidone.
28 . The composition of claim 21 , wherein the surface active biological modifier is selected from the group consisting of proteins, polysaccharides, and combinations thereof.
29 . The composition of claim 28 , wherein the polysaccharide is selected from the group consisting of starches, heparin and chitosans.
30 . The composition of claim 28 , wherein the protein is selected from the group consisting of albumin and casein.
31 . The composition of claim 20 , wherein the surface modifier comprises a copolymer of oxyethylene and oxypropylene.
32 . The composition of claim 31 , wherein the copolymer of oxyethylene and oxypropylene is a block copolymer.
33 . The composition of claim 20 , further comprising a pH adjusting agent.
34 . The composition of claim 20 , wherein the immunosuppressive agent is rapamycin.